233 related articles for article (PubMed ID: 16000944)
1. Allogeneic hematopoietic cell transplantation as immunotherapy for solid tumors: current status and future directions.
Lundqvist A; Childs R
J Immunother; 2005; 28(4):281-8. PubMed ID: 16000944
[TBL] [Abstract][Full Text] [Related]
2. [Allogeneic hematopoietic stem cell transplantation for solid tumors in the United States: a review].
Cheng YC; Ueno NT
Nihon Rinsho; 2003 Sep; 61(9):1619-34. PubMed ID: 14515734
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic stem cell transplantation for the treatment of advanced solid tumors.
Bregni M; Bernardi M; Ciceri F; Peccatori J
Springer Semin Immunopathol; 2004 Nov; 26(1-2):95-108. PubMed ID: 15378271
[TBL] [Abstract][Full Text] [Related]
4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
5. Nonmyeloablative transplantation for solid tumors: a new frontier for allogeneic immunotherapy.
Espinoza-Delgado I; Childs RW
Expert Rev Anticancer Ther; 2004 Oct; 4(5):865-75. PubMed ID: 15485320
[TBL] [Abstract][Full Text] [Related]
6. Advances in allogeneic stem cell transplantation: directing graft-versus-leukemia at solid tumors.
Childs R; Srinivasan R
Cancer J; 2002; 8(1):2-11. PubMed ID: 11895199
[TBL] [Abstract][Full Text] [Related]
7. Reduced-intensity hematopoietic stem cell transplantation (RIST) for solid malignancies.
Kami M; Makimoto A; Heike Y; Takaue Y
Jpn J Clin Oncol; 2004 Dec; 34(12):707-16. PubMed ID: 15640500
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic stem cell transplantation as immunotherapy for nonhematological cancers.
Srinivasan R; Barrett J; Childs R
Semin Oncol; 2004 Feb; 31(1):47-55. PubMed ID: 14970937
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens.
Tykodi SS; Warren EH; Thompson JA; Riddell SR; Childs RW; Otterud BE; Leppert MF; Storb R; Sandmaier BM
Clin Cancer Res; 2004 Dec; 10(23):7799-811. PubMed ID: 15585611
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies.
Pedrazzoli P; Da Prada GA; Giorgiani G; Schiavo R; Zambelli A; Giraldi E; Landonio G; Locatelli F; Siena S; Della Cuna GR
Cancer; 2002 May; 94(9):2409-15. PubMed ID: 12015766
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies.
Goldstein SC; Porter DL
Expert Rev Hematol; 2010 Jun; 3(3):301-14. PubMed ID: 21082981
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic immune replacement as cancer immunotherapy.
Chakrabarti S; Childs R
Expert Opin Biol Ther; 2003 Oct; 3(7):1051-60. PubMed ID: 14519070
[TBL] [Abstract][Full Text] [Related]
14. Adoptive allogeneic immunotherapy--history and future perspectives.
Schleuning M
Transfus Sci; 2000 Oct; 23(2):133-50. PubMed ID: 11035275
[TBL] [Abstract][Full Text] [Related]
15. Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors.
Demirer T; Barkholt L; Blaise D; Pedrazzoli P; Aglietta M; Carella AM; Bay JO; Arpaci F; Rosti G; Gurman G; Niederwieser D; Bregni M;
Nat Clin Pract Oncol; 2008 May; 5(5):256-67. PubMed ID: 18398414
[TBL] [Abstract][Full Text] [Related]
16. Immunobiology of allogeneic hematopoietic stem cell transplantation.
Welniak LA; Blazar BR; Murphy WJ
Annu Rev Immunol; 2007; 25():139-70. PubMed ID: 17129175
[TBL] [Abstract][Full Text] [Related]
17. Low-intensity allogeneic hematopoietic stem cell transplantation for myeloid malignancies: separating graft-versus-leukemia effects from graft-versus-host disease.
Burroughs L; Storb R
Curr Opin Hematol; 2005 Jan; 12(1):45-54. PubMed ID: 15604891
[TBL] [Abstract][Full Text] [Related]
18. A comparison between low intensity and reduced intensity conditioning in allogeneic hematopoietic stem cell transplantation for solid tumors.
Conrad R; Remberger M; Cederlund K; Ringdén O; Barkholt L
Haematologica; 2008 Feb; 93(2):265-72. PubMed ID: 18245651
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic hemopoietic stem cell transplantation in solid tumors.
Carnevale-Schianca F; Ricchiardi A; Capaldi A; Bucci AR; Grignani G; Rota-Scalabrini D; Fizzotti M; Aliberti S; Aglietta M
Transplant Proc; 2005; 37(6):2664-6. PubMed ID: 16182778
[TBL] [Abstract][Full Text] [Related]
20. Development of reduced-intensity hematopoietic stem cell transplantation in the National Cancer Center Hospital, Japan.
Kami M; Takaue Y
Ther Apher Dial; 2003 Jun; 7(3):318-28. PubMed ID: 12924607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
